SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Since the publication of the Society for Immunotherapy of Cancer’s (SITC) original cancer immunotherapy biomarkers resource document, there have been remarkable breakthroughs in cancer immunotherapy, in particular the development and approval of immune checkpoint inhibitors, engineered cellular ther...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/2/e000705.full |
id |
doaj-15ac320dfb9843698d79bbf6c3576138 |
---|---|
record_format |
Article |
spelling |
doaj-15ac320dfb9843698d79bbf6c35761382021-07-13T15:02:31ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-07-018210.1136/jitc-2020-000705SITC cancer immunotherapy resource document: a compass in the land of biomarker discoveryKavita Dhodapkar0Sumati Gupta1Yoshinobu Koguchi2Srabani Bhaumik3Cristina Maccalli4Sylvia Janetzki5Yingdong Zhao6Jean-Charles J B Grivel7Thomas O Kleen8Amanda W Lund9Yolanda D Mahnke10Ruslan D Novosiadly11Senthamil R Selvan12Tasha Sims133Emory University School of Medicine, Atlanta, GA, USAHuntsman Cancer Institute, Salt Lake City, Utah, USA1Providence Cancer Institute, Portland, OR, USARoche Tissue Diagnostics, Tucson, Arizona, USAResearch Department, Sidra Medicine, Doha, QatarZellNet Consulting Inc, Fort Lee, New Jersey, USANational Cancer Institute, Bethesda, Maryland, USAResearch Department, Sidra Medicine, Doha, QatarImmodulon Therapeutics Ltd, Uxbridge, UKOregon Health and Science University, Portland, Oregon, USAFlowKnowHow LLC, Brooklyn, New York, USABristol-Myers Squibb, Princeton, New Jersey, USABioMarker Strategies LLC, Rockville, Maryland, USARegeneron Pharmaceuticals Inc, Tarrytown, New York, USASince the publication of the Society for Immunotherapy of Cancer’s (SITC) original cancer immunotherapy biomarkers resource document, there have been remarkable breakthroughs in cancer immunotherapy, in particular the development and approval of immune checkpoint inhibitors, engineered cellular therapies, and tumor vaccines to unleash antitumor immune activity. The most notable feature of these breakthroughs is the achievement of durable clinical responses in some patients, enabling long-term survival. These durable responses have been noted in tumor types that were not previously considered immunotherapy-sensitive, suggesting that all patients with cancer may have the potential to benefit from immunotherapy. However, a persistent challenge in the field is the fact that only a minority of patients respond to immunotherapy, especially those therapies that rely on endogenous immune activation such as checkpoint inhibitors and vaccination due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers for each immunotherapy strategy, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement of immunotherapy. In this document, we summarize and update established biomarkers, guidelines, and regulatory considerations for clinical immune biomarker development, discuss well-known and novel technologies for biomarker discovery and validation, and provide tools and resources that can be used by the biomarker research community to facilitate the continued development of immuno-oncology and aid in the goal of durable responses in all patients.https://jitc.bmj.com/content/8/2/e000705.full |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kavita Dhodapkar Sumati Gupta Yoshinobu Koguchi Srabani Bhaumik Cristina Maccalli Sylvia Janetzki Yingdong Zhao Jean-Charles J B Grivel Thomas O Kleen Amanda W Lund Yolanda D Mahnke Ruslan D Novosiadly Senthamil R Selvan Tasha Sims |
spellingShingle |
Kavita Dhodapkar Sumati Gupta Yoshinobu Koguchi Srabani Bhaumik Cristina Maccalli Sylvia Janetzki Yingdong Zhao Jean-Charles J B Grivel Thomas O Kleen Amanda W Lund Yolanda D Mahnke Ruslan D Novosiadly Senthamil R Selvan Tasha Sims SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery Journal for ImmunoTherapy of Cancer |
author_facet |
Kavita Dhodapkar Sumati Gupta Yoshinobu Koguchi Srabani Bhaumik Cristina Maccalli Sylvia Janetzki Yingdong Zhao Jean-Charles J B Grivel Thomas O Kleen Amanda W Lund Yolanda D Mahnke Ruslan D Novosiadly Senthamil R Selvan Tasha Sims |
author_sort |
Kavita Dhodapkar |
title |
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery |
title_short |
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery |
title_full |
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery |
title_fullStr |
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery |
title_full_unstemmed |
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery |
title_sort |
sitc cancer immunotherapy resource document: a compass in the land of biomarker discovery |
publisher |
BMJ Publishing Group |
series |
Journal for ImmunoTherapy of Cancer |
issn |
2051-1426 |
publishDate |
2020-07-01 |
description |
Since the publication of the Society for Immunotherapy of Cancer’s (SITC) original cancer immunotherapy biomarkers resource document, there have been remarkable breakthroughs in cancer immunotherapy, in particular the development and approval of immune checkpoint inhibitors, engineered cellular therapies, and tumor vaccines to unleash antitumor immune activity. The most notable feature of these breakthroughs is the achievement of durable clinical responses in some patients, enabling long-term survival. These durable responses have been noted in tumor types that were not previously considered immunotherapy-sensitive, suggesting that all patients with cancer may have the potential to benefit from immunotherapy. However, a persistent challenge in the field is the fact that only a minority of patients respond to immunotherapy, especially those therapies that rely on endogenous immune activation such as checkpoint inhibitors and vaccination due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers for each immunotherapy strategy, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement of immunotherapy. In this document, we summarize and update established biomarkers, guidelines, and regulatory considerations for clinical immune biomarker development, discuss well-known and novel technologies for biomarker discovery and validation, and provide tools and resources that can be used by the biomarker research community to facilitate the continued development of immuno-oncology and aid in the goal of durable responses in all patients. |
url |
https://jitc.bmj.com/content/8/2/e000705.full |
work_keys_str_mv |
AT kavitadhodapkar sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT sumatigupta sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT yoshinobukoguchi sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT srabanibhaumik sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT cristinamaccalli sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT sylviajanetzki sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT yingdongzhao sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT jeancharlesjbgrivel sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT thomasokleen sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT amandawlund sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT yolandadmahnke sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT ruslandnovosiadly sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT senthamilrselvan sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery AT tashasims sitccancerimmunotherapyresourcedocumentacompassinthelandofbiomarkerdiscovery |
_version_ |
1721305131055579136 |